Data from an analysis of three randomized, placebo-controlled trials shows patients with moderate to severe plaque psoriasis receiving infliximab (Remicade) achieved a consistently high level of skin clearance in each of the four body regions.

At week 10 of the analysis, involving nearly 1,500 patients, 71 percent of those receiving Remicade at a dose of 3 milligrams per kilogram of body weight (mg/kg) and 79 percent of those receiving 5 mg/kg achieved a 75 percent or greater improvement in the chronic inflammatory condition based on the Psoriasis Area Severity Index (PASI), a widely used measure of disease severity. In contrast, only 3 percent of those on placebo experienced similar improvement. Additionally, 39 percent and 52 percent of patients receiving Remicade at 3 mg/kg and 5mg/kg, respectively, achieved a PASI 90, or nearly complete skin clearance, versus 1 percent of patients receiving placebo.

“This analysis shows that treatment with Remicade resulted in a consistently high level of clinical response in each quadrant of the body evaluated by PASI, and the results were consistent with patients’ overall psoriasis improvement,” says Alan Menter, MD, dermatologist, Baylor Research Institute, Dallas.  “Remicade remains an important advancement and biologic treatment option for a broad spectrum of patients with severe psoriasis.”

Investigators reported these Remicade-psoriasis findings at the 66th Annual Meeting of the American Academy of Dermatology.